acquisit support buy thesi pt
biopharma china capit alloc driver buy-thesi
host ken apicerno vice-president ir ndr last week strong
grew organ commentari reflect market healthi
momentum/posit remain strong biopharma estim
growth exposur lead posit fast-grow
segment incl bioproduct clinic trial research consum arguabl set
compani grow even faster go forward noth heard suggest
plausibl compar guidanc hsd china high teen recent
compound-annual-growth-rate remain key investor focu messag clear china strateg
initi plu scale posit point sustain strong growth year
come impact cap alloc key tenet buy thesi last
night brammer acquisit nice strateg tuck-in beyond deal
organ guid strongest ever initi guid recent comment
ceo marc casper suggest growth even stronger
bake conservat uncertainti incl macro china trade brexit though ir
feedback echo ceo recent comment trend date remain robust
henc slow rais forecast consensu still
see room upsid consid ytd trend management commentari plu dilig
brammer acquisit guid ep accret end close
sunday night announc acquisit privat held brammer
revenu multipl nearli pthn multipl brammer
growth pthn given special still nascent
rapidli grow gene therapi market strateg think deal make
sens pthn provid beachhead broaden market reach
valuat rais pt increas
confid higher growth rais forecast took dcf
impli ntm price-to-earnings vs current add ep
accret share yet complet gatan brammer arriv
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price edt
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
valuat method risk statement
discount cash flow primari valuat method dcf incorpor
wacc lt growth assumpt
industry-wid risk includ declin spend pharmaceut compani
due signific declin fund small compani promin
trial failur affect class drug deceler global growth
includ risk escal trade tension pressur academ
govern budget could result recessionari cost-cut
polit chang price pressur diagnost sector due
protect access medicar act pama chang competit dynam
includ disrupt new entrant certain technolog inabl
compani compet effect china critic growth market foreign
exchang fluctuat chang tax polici
risk
includ biopharma slow chines economi
integr recent larg make bad strateg decis futur
report prepar ub secur llc affili ub ag ub ag subsidiari branch affili
refer herein ub
inform way ub manag conflict maintain independ research product histor
perform inform certain addit disclosur concern ub research recommend pleas visit
www ub com/disclosur figur contain perform chart refer past past perform reliabl
indic futur result addit inform made avail upon request ub secur co limit licens
conduct secur invest consult busi china secur regulatori commiss ub act may act
princip debt secur relat deriv may subject report recommend
final march gmt ub design certain research depart member deriv
research analyst depart member publish research princip analysi price market
deriv provid inform reason suffici upon base decis enter deriv
transact deriv research analyst co-author research report equiti research analyst economist
deriv research analyst respons deriv invest view forecast and/or recommend
analyst certif research analyst primarili respons content research report whole part
certifi respect secur issuer analyst cover report view express
accur reflect person view secur issuer prepar independ manner
includ respect ub part compens directli indirectli relat
specif recommend view express research analyst research report
fsr mra
fsr mra
fsr mra
stock price expect rise within three month time
rate assign specif catalyst event
stock price expect fall within three month time
rate assign specif catalyst event
ub rate alloc decemb
compani coverag global within rate categori
compani within rate categori invest bank ib servic provid
within past month
compani coverag global within short-term rate categori
compani within short-term rate categori invest bank ib servic provid
within past month
definit forecast stock return fsr defin expect percentag price appreci plu gross dividend
yield next month case yield may base accru dividend market return assumpt
mra defin one-year local market interest rate plu proxi forecast equiti risk
premium review ur stock may flag ur analyst indic stock price target and/or
rate subject possibl chang near term usual respons event may affect invest case
valuat short-term rate reflect expect near-term three month perform stock
reflect chang fundament view invest case equiti price target invest horizon
except special case uk european invest fund rate definit buy posit
factor structur manag perform record discount neutral neutral factor structur
manag perform record discount sell neg factor structur manag perform record
discount band except cbe except standard band may grant invest
review committe irc factor consid irc includ stock volatil credit spread respect
compani debt result stock deem high low risk may subject higher lower band
relat rate except appli identifi compani disclosur tabl relev
research analyst contribut report employ non-u affili ub secur llc
registered/qualifi research analyst finra analyst may associ person ub secur llc
therefor subject finra restrict commun subject compani public appear
trade secur held research analyst account name affili analyst employ affili
contribut report follow
ub price local market close
rate tabl current publish rate prior report may recent stock
within past month ub secur llc and/or affili receiv compens product
servic invest bank servic company/ent
ub secur llc make market secur and/or adr compani
 -base global equiti strategist member team one household member posit
unless otherwis indic pleas refer valuat risk section within bodi report complet set
disclosur statement associ compani discuss report includ inform valuat risk
